Chris N. Barnes

638 total citations
33 papers, 471 citations indexed

About

Chris N. Barnes is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Chris N. Barnes has authored 33 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 9 papers in Physiology and 4 papers in Molecular Biology. Recurrent topics in Chris N. Barnes's work include Inhalation and Respiratory Drug Delivery (9 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (9 papers) and Asthma and respiratory diseases (8 papers). Chris N. Barnes is often cited by papers focused on Inhalation and Respiratory Drug Delivery (9 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (9 papers) and Asthma and respiratory diseases (8 papers). Chris N. Barnes collaborates with scholars based in United States, Australia and Canada. Chris N. Barnes's co-authors include Raymond P. Kelly, John Raftos, Ken Hillman, Kevin J. Graham, G. Nelson, M. F. O'Rourke, Anne Keogh, D. Baron, Glenn Crater and Srikanth Pendyala and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Chris N. Barnes

31 papers receiving 460 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris N. Barnes United States	10	168	139	137	112	63	33	471
Shapour Shirani Iran	12	138 0.8×	87 0.6×	111 0.8×	47 0.4×	28 0.4×	62	415
J Weber-Eibel Austria	5	185 1.1×	86 0.6×	77 0.6×	201 1.8×	70 1.1×	8	556
Ígor Mendonça Proença Brazil	10	64 0.4×	376 2.7×	172 1.3×	61 0.5×	55 0.9×	27	529
Anna Duprée Germany	12	55 0.3×	242 1.7×	118 0.9×	34 0.3×	44 0.7×	41	363
Ulrich Lotze Germany	14	438 2.6×	139 1.0×	88 0.6×	39 0.3×	17 0.3×	32	628
Benjamin J. Freda United States	9	338 2.0×	135 1.0×	108 0.8×	55 0.5×	12 0.2×	12	594
Paul Super United Kingdom	12	43 0.3×	451 3.2×	116 0.8×	69 0.6×	58 0.9×	35	542
Yalım Yalçın Türkiye	12	175 1.0×	103 0.7×	133 1.0×	16 0.1×	28 0.4×	33	379
G Grassi Italy	10	128 0.8×	195 1.4×	63 0.5×	17 0.2×	46 0.7×	47	354
Philippe Roméo Canada	8	289 1.7×	73 0.5×	98 0.7×	40 0.4×	8 0.1×	19	499

Countries citing papers authored by Chris N. Barnes

Since Specialization

Citations

This map shows the geographic impact of Chris N. Barnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris N. Barnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris N. Barnes more than expected).

Fields of papers citing papers by Chris N. Barnes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris N. Barnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris N. Barnes. The network helps show where Chris N. Barnes may publish in the future.

Co-authorship network of co-authors of Chris N. Barnes

This figure shows the co-authorship network connecting the top 25 collaborators of Chris N. Barnes. A scholar is included among the top collaborators of Chris N. Barnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris N. Barnes. Chris N. Barnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Montesi, Sydney B., Gregory P. Cosgrove, Scott Turner, et al.. (2025). Dual αvβ6 and αvβ1 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 211(7). 1229–1240. 3 indexed citations

Lancaster, Lisa, Vincent Cottin, Murali Ramaswamy, et al.. (2024). Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 210(4). 424–434. 35 indexed citations

Mooney, Joshua J., Susan S. Jacobs, Éric Lefebvre, et al.. (2024). Bexotegrast Shows Dose-Dependent Integrin αvβ6 Receptor Occupancy in Lungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical Trial. Annals of the American Thoracic Society. 22(3). 350–358. 8 indexed citations

Goldin, Jonathan, Chris N. Barnes, Martin Decaris, et al.. (2024). Evaluation of Quantitative Imaging in a Phase 2a Study for the Treatment of Idiopathic Pulmonary Fibrosis With Bexotegrast (INTEGRIS-IPF). A5082–A5082.

Daud, Adil, Chris N. Barnes, S. E. Owen, et al.. (2023). 714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors. SHILAP Revista de lepidopterología. A809–A809. 1 indexed citations

Abell, Thomas L., Braden Kuo, Tuba Esfandyari, et al.. (2023). A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis. Neurogastroenterology & Motility. 35(4). e14523–e14523. 9 indexed citations

Sarafoglou, Kyriakie, Chris N. Barnes, Michael Huang, et al.. (2021). Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies. The Journal of Clinical Endocrinology & Metabolism. 106(11). e4666–e4679. 22 indexed citations

Kuo, Braden, Chris N. Barnes, Deanna D. Nguyen, et al.. (2021). Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study. Alimentary Pharmacology & Therapeutics. 53(10). 1090–1097. 22 indexed citations

Siler, Thomas M., Edmund J. Moran, Chris N. Barnes, & Glenn Crater. (2020). Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 7(2). 99–106. 8 indexed citations

10.

Barnes, Chris N., Donald A. Mahler, Jill Ohar, David A. Lombardi, & Glenn Crater. (2020). Peak Inspiratory Flows. CHEST Journal. 158(4). 1413–1419. 11 indexed citations

11.

Donohue, James F., Edward Kerwin, Sanjay Sethi, et al.. (2019). Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine. 153. 38–43. 26 indexed citations

12.

Donohue, James F., Gregory Feldman, Sanjay Sethi, et al.. (2019). Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulmonary Pharmacology & Therapeutics. 57. 101808–101808. 9 indexed citations

13.

Niederman, Michael S., et al.. (2019). Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials. Infectious Diseases and Therapy. 8(3). 445–452. 2 indexed citations

14.

Borin, Marie T., Arthur Lo, Chris N. Barnes, Srikanth Pendyala, & David L. Bourdet. (2019). <p>Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function</p>. International Journal of COPD. Volume 14. 2305–2318. 5 indexed citations

15.

Ferguson, Gary T., Gregory Feldman, Chris N. Barnes, et al.. (2019). Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 6(2). 154–165. 23 indexed citations

16.

Donohue, James F., Edward Kerwin, Sanjay Sethi, et al.. (2019). Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease. SHILAP Revista de lepidopterología. 26. 104277–104277. 1 indexed citations

17.

Donohue, James F., et al.. (2017). The 24-Hour Profile of FEV1 After 12-Weeks Treatment With Revefenacin, a Once Daily Long-Acting Muscarinic Receptor Antagonists for Nebulization: A Spirometry Substudy. CHEST Journal. 152(4). A770–A770. 2 indexed citations

18.

Lawitz, Eric, et al.. (2015). P0898 : TD-6450, A next generation once-daily NS5A inhibitor, has potent antiviral activity following a 3-day monotherapy study in genotype 1 HCV infection. Journal of Hepatology. 62. S680–S681. 1 indexed citations

19.

Barnes, Chris N., David Lillicrap, Victor S. Blanchette, et al.. (2004). Novel and Clinically Significant Factors Influencing the Pharmacokinetic Variability of Recombinant Factor VIII (Kogenate-FS) in Children.. Blood. 104(11). 3991–3991. 2 indexed citations

20.

O'Rourke, M. F., D. Baron, Anne Keogh, et al.. (1988). Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator.. Circulation. 77(6). 1311–1315. 192 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact